{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["cancer", "deubiquitination", "ubiquitin inhibitors", "ubiquitin-proteasome system", "ubiquitination"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34769401", "DateCompleted": {"Year": "2021", "Month": "12", "Day": "10"}, "DateRevised": {"Year": "2022", "Month": "03", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "11", "Day": "04"}], "Language": ["eng"], "ELocationID": ["11971", "10.3390/ijms222111971"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "22", "Issue": "21", "PubDate": {"Year": "2021", "Month": "Nov", "Day": "04"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling.", "Abstract": {"AbstractText": ["The ubiquitin-proteasome pathway (UPP) is involved in regulating several biological functions, including cell cycle control, apoptosis, DNA damage response, and apoptosis. It is widely known for its role in degrading abnormal protein substrates and maintaining physiological body functions via ubiquitinating enzymes (E1, E2, E3) and the proteasome. Therefore, aberrant expression in these enzymes results in an altered biological process, including transduction signaling for cell death and survival, resulting in cancer. In this review, an overview of profuse enzymes involved as a pro-oncogenic or progressive growth factor in tumors with their downstream signaling pathways has been discussed. A systematic literature review of PubMed, Medline, Bentham, Scopus, and EMBASE (Elsevier) databases was carried out to understand the nature of the extensive work done on modulation of ubiquitin-proteasome pathways in oncogenic signaling. Various in vitro, in vivo studies demonstrating the involvement of ubiquitin-proteasome systems in varied types of cancers and the downstream signaling pathways involved are also discussed in the current review. Several inhibitors of E1, E2, E3, deubiquitinase enzymes and proteasome have been applied for treating cancer. Some of these drugs have exhibited successful outcomes in in vivo studies on different cancer types, so clinical trials are going on for these inhibitors. This review mainly focuses on certain ubiquitin-proteasome enzymes involved in developing cancers and certain enzymes that can be targeted to treat cancer."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, India."}], "LastName": "Sharma", "ForeName": "Anmol", "Initials": "A"}, {"Identifier": ["0000-0001-5172-3135"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, India."}], "LastName": "Khan", "ForeName": "Heena", "Initials": "H"}, {"Identifier": ["0000-0003-2979-1590"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, India."}], "LastName": "Singh", "ForeName": "Thakur Gurjeet", "Initials": "TG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, India."}], "LastName": "Grewal", "ForeName": "Amarjot Kaur", "Initials": "AK"}, {"Identifier": ["0000-0002-1185-8884"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Vegetable Crops and Medicinal Plants, University of Life Sciences in Lublin, 50A Do\u015bwiadczalna Street, 20-280 Lublin, Poland."}], "LastName": "Najda", "ForeName": "Agnieszka", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Vegetable Crops and Medicinal Plants, University of Life Sciences in Lublin, 50A Do\u015bwiadczalna Street, 20-280 Lublin, Poland."}], "LastName": "Kawecka-Radomska", "ForeName": "Ma\u0142gorzata", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicine and Infectious Diseases, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt."}], "LastName": "Kamel", "ForeName": "Mohamed", "Initials": "M"}, {"Identifier": ["0000-0001-6210-3628"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, P.O. Box 80260, Jeddah 21589, Saudi Arabia."}], "LastName": "Altyar", "ForeName": "Ahmed E", "Initials": "AE"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, Jeddah 21442, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt."}], "LastName": "Abdel-Daim", "ForeName": "Mohamed M", "Initials": "MM"}], "GrantList": [{"GrantID": "TURSP-2020/ 93", "Agency": "Taif University", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Ubiquitin"}, {"RegistryNumber": "EC 2.3.2.27", "NameOfSubstance": "Ubiquitin-Protein Ligases"}, {"RegistryNumber": "EC 3.4.25.1", "NameOfSubstance": "Proteasome Endopeptidase Complex"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "enzymology", "pathology"], "DescriptorName": "Neoplasms"}, {"QualifierName": ["chemistry"], "DescriptorName": "Proteasome Endopeptidase Complex"}, {"QualifierName": ["metabolism"], "DescriptorName": "Ubiquitin"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Ubiquitin-Protein Ligases"}, {"QualifierName": [], "DescriptorName": "Ubiquitination"}], "CoiStatement": "The authors declare that they have no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Martin G.S. Cell signaling and cancer. Cancer Cell. 2003;4:167\u2013174. doi: 10.1016/S1535-6108(03)00216-2.", "ArticleIdList": ["10.1016/S1535-6108(03)00216-2", "14522250"]}, {"Citation": "Sever R., Brugge J.S. Signaling in cancer. Cold Spring Harb. Perspect. Med. 2014;5:a006098. doi: 10.1101/cshperspect.a006098.", "ArticleIdList": ["10.1101/cshperspect.a006098", "PMC4382731", "25833940"]}, {"Citation": "Huangfu W.C., Fuchs S.Y. Ubiquitination-dependent regulation of signaling receptors in cancer. Genes Cancer. 2010;1:725\u2013734. doi: 10.1177/1947601910382901.", "ArticleIdList": ["10.1177/1947601910382901", "PMC2994580", "21127735"]}, {"Citation": "Nepal S., Shrestha A., Park P.H. Ubiquitin specific protease 2 acts as a key modulator for the regulation of cell cycle by adiponectin and leptin in cancer cells. Mol. Cell. Endocrinol. 2015;412:44\u201355. doi: 10.1016/j.mce.2015.05.029.", "ArticleIdList": ["10.1016/j.mce.2015.05.029", "26033248"]}, {"Citation": "Spataro V., Norbury C., Harris A.L. The ubiquitin-proteasome pathway in cancer. Br. J. Cancer. 1998;77:448\u2013455. doi: 10.1038/bjc.1998.71.", "ArticleIdList": ["10.1038/bjc.1998.71", "PMC2151296", "9472642"]}, {"Citation": "Smalle J., Vierstra R.D. The ubiquitin 26S proteasome proteolytic pathway. Annu. Rev. Plant Biol. 2004;55:555\u2013590. doi: 10.1146/annurev.arplant.55.031903.141801.", "ArticleIdList": ["10.1146/annurev.arplant.55.031903.141801", "15377232"]}, {"Citation": "Dikic I., Wakatsuki S., Walters K.J. Ubiquitin-binding domains\u2014from structures to functions. Nat. Rev. Mol. Cell Biol. 2009;10:659\u2013671. doi: 10.1038/nrm2767.", "ArticleIdList": ["10.1038/nrm2767", "PMC7359374", "19773779"]}, {"Citation": "Deng L., Meng T., Chen L., Wei W., Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct. Target. Ther. 2020;5:11. doi: 10.1038/s41392-020-0107-0.", "ArticleIdList": ["10.1038/s41392-020-0107-0", "PMC7048745", "32296023"]}, {"Citation": "Swatek K.N., Komander D. Ubiquitin modifications. Cell Res. 2016;26:399\u2013422. doi: 10.1038/cr.2016.39.", "ArticleIdList": ["10.1038/cr.2016.39", "PMC4822133", "27012465"]}, {"Citation": "Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325:834\u2013840. doi: 10.1126/science.1175371.", "ArticleIdList": ["10.1126/science.1175371", "19608861"]}, {"Citation": "Weinert B.T., Sch\u00f6lz C., Wagner S.A., Iesmantavicius V., Su D., Daniel J.A., Choudhary C. Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep. 2013;4:842\u2013851. doi: 10.1016/j.celrep.2013.07.024.", "ArticleIdList": ["10.1016/j.celrep.2013.07.024", "23954790"]}, {"Citation": "Ferreira de Freitas R., Harding R.J., Franzoni I., Ravichandran M., Mann M.K., Ouyang H., Lautens M., Santhakumar V., Arrowsmith C.H., Schapira M. Identification and structure\u2013activity relationship of HDAC6 zinc-finger ubiquitin binding domain inhibitors. J. Med. Chem. 2018;61:4517\u20134527. doi: 10.1021/acs.jmedchem.8b00258.", "ArticleIdList": ["10.1021/acs.jmedchem.8b00258", "29741882"]}, {"Citation": "Scott D., Oldham N.J., Strachan J., Searle M.S., Layfield R. Ubiquitin-binding domains: Mechanisms of ubiquitin recognition and use as tools to investigate ubiquitin-modified proteomes. Proteomics. 2015;15:844\u2013861. doi: 10.1002/pmic.201400341.", "ArticleIdList": ["10.1002/pmic.201400341", "25327553"]}, {"Citation": "Randles L., Walters K.J. Ubiquitin and its binding domains. Front. Biosci. 2012;17:2140. doi: 10.2741/4042.", "ArticleIdList": ["10.2741/4042", "PMC6295927", "22652769"]}, {"Citation": "Hurley J.H., Lee S., Prag G. Ubiquitin-binding domains. Biochem. J. 2006;399:361\u2013372. doi: 10.1042/BJ20061138.", "ArticleIdList": ["10.1042/BJ20061138", "PMC1615911", "17034365"]}, {"Citation": "Baumeister W., Walz J., Z\u00fchl F., Seem\u00fcller E. The proteasome: Paradigm of a self-compartmentalizing protease. Cell. 1998;92:367\u2013380. doi: 10.1016/S0092-8674(00)80929-0.", "ArticleIdList": ["10.1016/S0092-8674(00)80929-0", "9476896"]}, {"Citation": "DeMartino G.N., Gillette T.G. Proteasomes: Machines for all reasons. Cell. 2007;129:659\u2013662. doi: 10.1016/j.cell.2007.05.007.", "ArticleIdList": ["10.1016/j.cell.2007.05.007", "17512401"]}, {"Citation": "Saeki Y., Tanaka K. Assembly and function of the proteasome. Ubiquitin Fam. Modif. Proteasome. 2012;832:315\u2013337.", "ArticleIdList": ["22350895"]}, {"Citation": "Tian G., Park S., Lee M.J., Huck B., McAllister F., Hill C.P., Gygi S.P., Finley D. An asymmetric interface between the regulatory and core particles of the proteasome. Nat. Struct. Mol. Biol. 2011;18:1259\u20131267. doi: 10.1038/nsmb.2147.", "ArticleIdList": ["10.1038/nsmb.2147", "PMC3210322", "22037170"]}, {"Citation": "Gillette T.G., Kumar B., Thompson D., Slaughter C.A., DeMartino G.N. Differential roles of the COOH termini of AAA subunits of PA700 (19 S regulator) in asymmetric assembly and activation of the 26 S proteasome. J. Biol. Chem. 2008;283:31813\u201331822. doi: 10.1074/jbc.M805935200.", "ArticleIdList": ["10.1074/jbc.M805935200", "PMC2581596", "18796432"]}, {"Citation": "Bard J.A., Goodall E.A., Greene E.R., Jonsson E., Dong K.C., Martin A. Structure and function of the 26S proteasome. Annu. Rev. Biochem. 2018;87:697\u2013724. doi: 10.1146/annurev-biochem-062917-011931.", "ArticleIdList": ["10.1146/annurev-biochem-062917-011931", "PMC6422034", "29652515"]}, {"Citation": "Tanaka K. The proteasome: Overview of structure and functions. Proc. Jpn. Acad. Ser. B. 2009;85:12\u201336. doi: 10.2183/pjab.85.12.", "ArticleIdList": ["10.2183/pjab.85.12", "PMC3524306", "19145068"]}, {"Citation": "Marshall R.S., Vierstra R.D. Dynamic regulation of the 26S proteasome: From synthesis to degradation. Front. Mol. Biosci. 2019;6:40. doi: 10.3389/fmolb.2019.00040.", "ArticleIdList": ["10.3389/fmolb.2019.00040", "PMC6568242", "31231659"]}, {"Citation": "Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem. 2009;78:477\u2013513. doi: 10.1146/annurev.biochem.78.081507.101607.", "ArticleIdList": ["10.1146/annurev.biochem.78.081507.101607", "PMC3431160", "19489727"]}, {"Citation": "Glickman M.H., Rubin D.M., Coux O., Wefes I., Pfeifer G., Cjeka Z., Baumeister W., Fried V.A., Finley D. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell. 1998;94:615\u2013623. doi: 10.1016/S0092-8674(00)81603-7.", "ArticleIdList": ["10.1016/S0092-8674(00)81603-7", "9741626"]}, {"Citation": "Scheel H., Hofmann K. Prediction of a common structural scaffold for proteasome lid, COP9-signalosome and eIF3 complexes. BMC Bioinform. 2005;6:71. doi: 10.1186/1471-2105-6-71.", "ArticleIdList": ["10.1186/1471-2105-6-71", "PMC1274264", "15790418"]}, {"Citation": "Bhattacharyya S., Yu H., Mim C., Matouschek A. Regulated protein turnover: Snapshots of the proteasome in action. Nat. Rev. Mol. Cell Biol. 2014;15:122\u2013133. doi: 10.1038/nrm3741.", "ArticleIdList": ["10.1038/nrm3741", "PMC4384331", "24452470"]}, {"Citation": "Nijman S.M., Luna-Vargas M.P., Velds A., Brummelkamp T.R., Dirac A.M., Sixma T.K., Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell. 2005;123:773\u2013786. doi: 10.1016/j.cell.2005.11.007.", "ArticleIdList": ["10.1016/j.cell.2005.11.007", "16325574"]}, {"Citation": "Reyes-Turcu F.E., Ventii K.H., Wilkinson K.D. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem. 2009;78:363\u2013397. doi: 10.1146/annurev.biochem.78.082307.091526.", "ArticleIdList": ["10.1146/annurev.biochem.78.082307.091526", "PMC2734102", "19489724"]}, {"Citation": "Clague M.J., Barsukov I., Coulson J.M., Liu H., Rigden D.J., Urb\u00e9 S. Deubiquitylases from genes to organism. Physiological. Rev. 2013;93:1289\u20131315. doi: 10.1152/physrev.00002.2013.", "ArticleIdList": ["10.1152/physrev.00002.2013", "23899565"]}, {"Citation": "Komander D., Clague M.J., Urb\u00e9 S. Breaking the chains: Structure and function of the deubiquitinases. Nat. Rev. Mol. Cell Biol. 2009;10:550\u2013563. doi: 10.1038/nrm2731.", "ArticleIdList": ["10.1038/nrm2731", "19626045"]}, {"Citation": "Rehman S.A., Kristariyanto Y.A., Choi S.Y., Nkosi P.J., Weidlich S., Labib K., Hofmann K., Kulathu Y. MINDY-1 is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes. Mol. Cell. 2016;63:146\u2013155.", "ArticleIdList": ["PMC4942677", "27292798"]}, {"Citation": "Mevissen T.E., Komander D. Mechanisms of deubiquitinase specificity and regulation. Annu. Rev. Biochem. 2017;86:159\u2013192. doi: 10.1146/annurev-biochem-061516-044916.", "ArticleIdList": ["10.1146/annurev-biochem-061516-044916", "28498721"]}, {"Citation": "Ramakrishna S., Suresh B., Baek K.H. The role of deubiquitinating enzymes in apoptosis. Cell. Mol. Life Sci. 2011;68:15\u201326. doi: 10.1007/s00018-010-0504-6.", "ArticleIdList": ["10.1007/s00018-010-0504-6", "20730552"]}, {"Citation": "Hermanns T., Hofmann K. Bacterial DUBs: Deubiquitination beyond the seven classes. Biochem. Soc. Trans. 2019;47:1857\u20131866. doi: 10.1042/BST20190526.", "ArticleIdList": ["10.1042/BST20190526", "31845741"]}, {"Citation": "Tsakiri E.N., Trougakos I.P. The amazing ubiquitin-proteasome system: Structural components and implication in aging. Int. Rev. Cell Mol. Biol. 2015;314:171\u2013237.", "ArticleIdList": ["25619718"]}, {"Citation": "Pelzer C., Kassner I., Matentzoglu K., Singh R.K., Wollscheid H.P., Scheffner M., Schmidtke G., Groettrup M. UBE1L2, a Novel E1 Enzyme Specific for Ubiquitin. J. Biol. Chem. 2007;282:23010\u201323014. doi: 10.1074/jbc.C700111200.", "ArticleIdList": ["10.1074/jbc.C700111200", "17580310"]}, {"Citation": "Kulkarni M., Smith H.E. E1 ubiquitin-activating enzyme UBA-1 plays multiple roles throughout C. elegans development. PLoS Genet. 2008;4:e1000131.", "ArticleIdList": ["PMC2443343", "18636104"]}, {"Citation": "Lee I., Schindelin H. Structural insights into E1-catalyzed ubiquitin activation and transfer to conjugating enzymes. Cell. 2008;134:268\u2013278. doi: 10.1016/j.cell.2008.05.046.", "ArticleIdList": ["10.1016/j.cell.2008.05.046", "18662542"]}, {"Citation": "Allan D.C., Phillips J.C. Evolution of the ubiquitin-activating enzyme Uba1 (E1) Phys. A Stat. Mech. Appl. 2017;483:456\u2013461. doi: 10.1016/j.physa.2017.04.144.", "ArticleIdList": ["10.1016/j.physa.2017.04.144"]}, {"Citation": "Zhou M.J., Chen F.Z., Chen H.C. Ubiquitination involved enzymes and cancer. Med. Oncol. 2014;31:93. doi: 10.1007/s12032-014-0093-6.", "ArticleIdList": ["10.1007/s12032-014-0093-6", "25023052"]}, {"Citation": "Van Wijk S.J., Timmers H.M. The family of ubiquitin-conjugating enzymes (E2s): Deciding between life and death of proteins. FASEB J. 2010;24:981\u2013993. doi: 10.1096/fj.09-136259.", "ArticleIdList": ["10.1096/fj.09-136259", "19940261"]}, {"Citation": "Stewart M.D., Ritterhoff T., Klevit R.E., Brzovic P.S. E2 enzymes: More than just middle men. Cell Res. 2016;26:423\u2013440. doi: 10.1038/cr.2016.35.", "ArticleIdList": ["10.1038/cr.2016.35", "PMC4822130", "27002219"]}, {"Citation": "Deshaies R.J., Joazeiro C.A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 2009;78:399\u2013434. doi: 10.1146/annurev.biochem.78.101807.093809.", "ArticleIdList": ["10.1146/annurev.biochem.78.101807.093809", "19489725"]}, {"Citation": "Zheng N., Shabek N. Ubiquitin ligases: Structure, function, and regulation. Annu. Rev. Biochem. 2017;86:129\u2013157. doi: 10.1146/annurev-biochem-060815-014922.", "ArticleIdList": ["10.1146/annurev-biochem-060815-014922", "28375744"]}, {"Citation": "Balaji V., Hoppe T. Regulation of E3 ubiquitin ligases by homotypic and heterotypic assembly. F1000Research. 2020;9:88. doi: 10.12688/f1000research.21253.1.", "ArticleIdList": ["10.12688/f1000research.21253.1", "PMC7005916", "32076548"]}, {"Citation": "Metzger M.B., Hristova V.A., Weissman A.M. HECT and RING finger families of E3 ubiquitin ligases at a glance. J. Cell Sci. 2012;125:531\u2013537. doi: 10.1242/jcs.091777.", "ArticleIdList": ["10.1242/jcs.091777", "PMC3381717", "22389392"]}, {"Citation": "Sluimer J., Distel B. Regulating the human HECT E3 ligases. Cell. Mol. Life Sci. 2018;75:3121\u20133141. doi: 10.1007/s00018-018-2848-2.", "ArticleIdList": ["10.1007/s00018-018-2848-2", "PMC6063350", "29858610"]}, {"Citation": "Martino L., Brown N.R., Masino L., Esposito D., Rittinger K. Determinants of E2-ubiquitin conjugate recognition by RBR E3 ligases. Sci. Rep. 2018;8:68. doi: 10.1038/s41598-017-18513-5.", "ArticleIdList": ["10.1038/s41598-017-18513-5", "PMC5758712", "29311602"]}, {"Citation": "Walden H., Rittinger K. RBR ligase\u2013mediated ubiquitin transfer: A tale with many twists and turns. Nat. Struct. Mol. Biol. 2018;25:440\u2013445. doi: 10.1038/s41594-018-0063-3.", "ArticleIdList": ["10.1038/s41594-018-0063-3", "29735995"]}, {"Citation": "Khan H., Gupta A., Singh T.G., Kaur A. Mechanistic insight on the role of leukotriene receptors in ischemic\u2013reperfusion injury. Pharmacol. Rep. 2021;73:1240\u20131254. doi: 10.1007/s43440-021-00258-8.", "ArticleIdList": ["10.1007/s43440-021-00258-8", "33818747"]}, {"Citation": "Popovic D., Vucic D., Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat. Med. 2014;20:1242\u20131253. doi: 10.1038/nm.3739.", "ArticleIdList": ["10.1038/nm.3739", "25375928"]}, {"Citation": "Rehni A.K., Singh T.G., Behl N., Arora S. Possible involvement of ubiquitin proteasome system and other proteases in acute and delayed aspects of ischemic preconditioning of brain in mice. Biol. Pharm. Bull. 2010;33:1953\u20131957. doi: 10.1248/bpb.33.1953.", "ArticleIdList": ["10.1248/bpb.33.1953", "21139232"]}, {"Citation": "Caldeira M.V., Salazar I.L., Curcio M., Canzoniero L.M., Duarte C.B. Role of the ubiquitin\u2013proteasome system in brain ischemia: Friend or foe? Prog. Neurobiol. 2014;112:50\u201369. doi: 10.1016/j.pneurobio.2013.10.003.", "ArticleIdList": ["10.1016/j.pneurobio.2013.10.003", "24157661"]}, {"Citation": "Zheng Q., Huang T., Zhang L., Zhou Y., Luo H., Xu H., Wang X. Dysregulation of ubiquitin-proteasome system in neurodegenerative diseases. Front. Aging Neurosci. 2016;8:303. doi: 10.3389/fnagi.2016.00303.", "ArticleIdList": ["10.3389/fnagi.2016.00303", "PMC5156861", "28018215"]}, {"Citation": "Kostin S., Pool L., Els\u00e4sser A., Hein S., Drexler H.C., Arnon E., Hayakawa Y., Zimmermann R., Bauer E., Kl\u00f6vekorn W.P., et al. Myocytes die by multiple mechanisms in failing human hearts. Circ. Res. 2003;92:715\u2013724. doi: 10.1161/01.RES.0000067471.95890.5C.", "ArticleIdList": ["10.1161/01.RES.0000067471.95890.5C", "12649263"]}, {"Citation": "Eefting F., Rensing B., Wigman J., Pannekoek W.J., Liu W.M., Cramer M.J., Lips D.J., Doevendans P.A. Role of apoptosis in reperfusion injury. Cardiovasc. Res. 2004;61:414\u2013426. doi: 10.1016/j.cardiores.2003.12.023.", "ArticleIdList": ["10.1016/j.cardiores.2003.12.023", "14962473"]}, {"Citation": "Shukla S.K., Rafiq K. Proteasome biology and therapeutics in cardiac diseases. Transl. Res. 2019;205:64\u201376. doi: 10.1016/j.trsl.2018.09.003.", "ArticleIdList": ["10.1016/j.trsl.2018.09.003", "PMC6372329", "30342797"]}, {"Citation": "Attaix D., Ventadour S., Codran A., B\u00e9chet D., Taillandier D., Combaret L. The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem. 2005;41:173\u2013186. doi: 10.1042/bse0410173.", "ArticleIdList": ["10.1042/bse0410173", "16250905"]}, {"Citation": "Lv C., Wang X., Guo Y., Yuan S. Role of Selective Autophagy in Spermatogenesis and Male Fertility. Cells. 2020;9:2523. doi: 10.3390/cells9112523.", "ArticleIdList": ["10.3390/cells9112523", "PMC7700316", "33238415"]}, {"Citation": "Hauser P.V., Perco P., M\u00fchlberger I., Pippin J., Blonski M., Mayer B., Alpers C.E., Oberbauer R., Shankland S.J. Microarray and bioinformatics analysis of gene expression in experimental membranous nephropathy. Nephron Exp. Nephrol. 2009;112:e43\u2013e58. doi: 10.1159/000213505.", "ArticleIdList": ["10.1159/000213505", "PMC3860588", "19390219"]}, {"Citation": "Kortenoeven M.L., Fenton R.A. Renal aquaporins and water balance disorders. Biochim. Biophys. Acta Gen. Subj. 2014;1840:1533\u20131549. doi: 10.1016/j.bbagen.2013.12.002.", "ArticleIdList": ["10.1016/j.bbagen.2013.12.002", "24342488"]}, {"Citation": "Sharma V., Kaur A., Singh T.G. Counteracting role of nuclear factor erythroid 2-related factor 2 pathway in Alzheimer\u2019s disease. Biomed. Pharmacother. 2020;129:110373. doi: 10.1016/j.biopha.2020.110373.", "ArticleIdList": ["10.1016/j.biopha.2020.110373", "32603894"]}, {"Citation": "Gao C., Huang W., Kanasaki K., Xu Y. The role of ubiquitination and sumoylation in diabetic nephropathy. BioMed Res. Int. 2014;2014:160692. doi: 10.1155/2014/160692.", "ArticleIdList": ["10.1155/2014/160692", "PMC4065738", "24991536"]}, {"Citation": "Siegel R.L., Miller K.D., Goding Sauer A., Fedewa S.A., Butterly L.F., Anderson J.C., Cercek A., Smith R.A., Jemal A. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 2020;70:145\u2013164. doi: 10.3322/caac.21601.", "ArticleIdList": ["10.3322/caac.21601", "32133645"]}, {"Citation": "Williams G.H., Stoeber K. The cell cycle and cancer. J. Pathol. 2012;226:352\u2013364. doi: 10.1002/path.3022.", "ArticleIdList": ["10.1002/path.3022", "21990031"]}, {"Citation": "Thanikachalam K., Khan G. Colorectal cancer and nutrition. Nutrients. 2019;11:164. doi: 10.3390/nu11010164.", "ArticleIdList": ["10.3390/nu11010164", "PMC6357054", "30646512"]}, {"Citation": "Sporn M.B. TGF-\u03b2: 20 years and counting. Microbes Infect. 1999;1:1251\u20131253. doi: 10.1016/S1286-4579(99)00260-9.", "ArticleIdList": ["10.1016/S1286-4579(99)00260-9", "10611752"]}, {"Citation": "Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685\u2013700. doi: 10.1016/S0092-8674(03)00432-X.", "ArticleIdList": ["10.1016/S0092-8674(03)00432-X", "12809600"]}, {"Citation": "Glasgow E., Mishra L. Transforming growth factor-\u03b2 signaling and ubiquitinators in cancer. Endocr. Relat. Cancer. 2008;15:59\u201372. doi: 10.1677/ERC-07-0168.", "ArticleIdList": ["10.1677/ERC-07-0168", "PMC3821554", "18310276"]}, {"Citation": "Stolz A., Neufeld K., Ertych N., Bastians H. Wnt-mediated protein stabilization ensures proper mitotic microtubule assembly and chromosome segregation. EMBO Rep. 2015;16:490\u2013499. doi: 10.15252/embr.201439410.", "ArticleIdList": ["10.15252/embr.201439410", "PMC4388615", "25656539"]}, {"Citation": "Chen Y., Li Y., Xue J., Gong A., Yu G., Zhou A., Lin K., Zhang S., Zhang N., Gottardi C.J., et al. Wnt-induced deubiquitination FoxM1 ensures nucleus \u03b2-catenin transactivation. EMBO J. 2016;35:668\u2013684. doi: 10.15252/embj.201592810.", "ArticleIdList": ["10.15252/embj.201592810", "PMC4801947", "26912724"]}, {"Citation": "Sun H., Ou B., Zhao S., Liu X., Song L., Liu X., Wang R., Peng Z. USP11 promotes growth and metastasis of colorectal cancer via PPP1CA-mediated activation of ERK/MAPK signaling pathway. EBioMedicine. 2019;48:236\u2013247. doi: 10.1016/j.ebiom.2019.08.061.", "ArticleIdList": ["10.1016/j.ebiom.2019.08.061", "PMC6838424", "31521612"]}, {"Citation": "Yun S.I., Hong H.K., Yeo S.Y., Kim S.H., Cho Y.B., Kim K.K. Ubiquitin-specific protease 21 promotes colorectal cancer metastasis by acting as a Fra-1 deubiquitinase. Cancers. 2020;12:207. doi: 10.3390/cancers12010207.", "ArticleIdList": ["10.3390/cancers12010207", "PMC7017141", "31947604"]}, {"Citation": "Liang Q., Tang C., Tang M., Zhang Q., Gao Y., Ge Z. TRIM47 is up-regulated in colorectal cancer, promoting ubiquitination and degradation of SMAD4. J. Exp. Clin. Cancer Res. 2019;38:159. doi: 10.1186/s13046-019-1143-x.", "ArticleIdList": ["10.1186/s13046-019-1143-x", "PMC6461818", "30979374"]}, {"Citation": "Wu X., Liu G., Liu R., He J., Wang G., Zhang H., Liu T., Bai J., Cheng N., Qiu J. Expression of ubiquitin conjugating enzyme E2T in colorectal cancers and clinical implications. Oncol. Lett. 2020;20:275. doi: 10.3892/ol.2020.12138.", "ArticleIdList": ["10.3892/ol.2020.12138", "PMC7520753", "33014154"]}, {"Citation": "Hao Z., Zhang H., Cowell J. Ubiquitin-conjugating enzyme UBE2C: Molecular biology, role in tumorigenesis, and potential as a biomarker. Tumor Biol. 2012;33:723\u2013730. doi: 10.1007/s13277-011-0291-1.", "ArticleIdList": ["10.1007/s13277-011-0291-1", "22170434"]}, {"Citation": "Zhang H., Sun W., Qiao G., Zhao B., Liu X., Zhu F. The Expression of Tripartite Motif Protein 36 and \u03b2-Catenin Correlates with the Prognosis of Esophageal Cancer. Gastroenterol. Res. Pract. 2020;2020:7641761. doi: 10.1155/2020/7641761.", "ArticleIdList": ["10.1155/2020/7641761", "PMC7415112", "32802046"]}, {"Citation": "Kawaguchi T., Komatsu S., Ichikawa D., Hirajima S., Nishimura Y., Konishi H., Shiozaki A., Fujiwara H., Okamoto K., Tsuda H., et al. Overexpression of TRIM44 is related to invasive potential and malignant outcomes in esophageal squamous cell carcinoma. Tumor Biol. 2017;39:1010428317700409. doi: 10.1177/1010428317700409.", "ArticleIdList": ["10.1177/1010428317700409", "28618928"]}, {"Citation": "Zheng L., Zhao Z., Rong L., Xue L., Song Y. RASSF6-TRIM16 axis promotes cell proliferation, migration and invasion in esophageal squamous cell carcinoma. J. Genet. Genom. 2019;46:477\u2013488. doi: 10.1016/j.jgg.2019.10.004.", "ArticleIdList": ["10.1016/j.jgg.2019.10.004", "31812473"]}, {"Citation": "Wang L., Hou Z., Hasim A., Abuduerheman A., Zhang H., Niyaz M., Awut I., Upur H., Sheyhidin I. RNF113A promotes the proliferation, migration and invasion, and is associated with a poor prognosis of esophageal squamous cell carcinoma. Int. J. Oncol. 2018;52:861\u2013871. doi: 10.3892/ijo.2018.4253.", "ArticleIdList": ["10.3892/ijo.2018.4253", "29393393"]}, {"Citation": "Singh S., Saraya A., Das P., Sharma R. Increased expression of MARCH8, an E3 ubiquitin ligase, is associated with growth of esophageal tumor. Cancer Cell Int. 2017;17:116. doi: 10.1186/s12935-017-0490-y.", "ArticleIdList": ["10.1186/s12935-017-0490-y", "PMC5715508", "29213217"]}, {"Citation": "Gupta A., Shah K., Oza M.J., Behl T. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. Biomed. Pharmacother. 2019;109:484\u2013492. doi: 10.1016/j.biopha.2018.10.155.", "ArticleIdList": ["10.1016/j.biopha.2018.10.155", "30551517"]}, {"Citation": "Chen Y., Fu D., Xi J., Ji Z., Liu T., Ma Y., Zhao Y., Dong L., Wang Q., Shen X. Expression and clinical significance of UCH37 in human esophageal squamous cell carcinoma. Dig. Dis. Sci. 2012;57:2310\u20132317. doi: 10.1007/s10620-012-2181-9.", "ArticleIdList": ["10.1007/s10620-012-2181-9", "22615012"]}, {"Citation": "Zhang W., Zhuang Y., Zhang Y., Yang X., Zhang H., Wang G., Yin W., Wang R., Zhang Z., Xiao W. Uev1A facilitates osteosarcoma differentiation by promoting Smurf1-mediated Smad1 ubiquitination and degradation. Cell Death Dis. 2017;8:e2974. doi: 10.1038/cddis.2017.366.", "ArticleIdList": ["10.1038/cddis.2017.366", "PMC5596555", "28771228"]}, {"Citation": "Kim B.G., Lee J.H., Yasuda J., Ryoo H.M., Cho J.Y. Phospho-Smad1 modulation by nedd4 e3 ligase in BMP/TGF-\u03b2 signaling. J. Bone Miner. Res. 2011;26:1411\u20131424. doi: 10.1002/jbmr.348.", "ArticleIdList": ["10.1002/jbmr.348", "21308777"]}, {"Citation": "Georges A., Marcon E., Greenblatt J., Frappier L. Identification and characterization of USP7 targets in cancer cells. Sci. Rep. 2018;8:15833. doi: 10.1038/s41598-018-34197-x.", "ArticleIdList": ["10.1038/s41598-018-34197-x", "PMC6203733", "30367141"]}, {"Citation": "Williams S.A., Maecker H.L., French D.M., Liu J., Gregg A., Silverstein L.B., Cao T.C., Carano R.A., Dixit V.M. USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell. 2011;146:918\u2013930. doi: 10.1016/j.cell.2011.07.040.", "ArticleIdList": ["10.1016/j.cell.2011.07.040", "21925315"]}, {"Citation": "Zhang P., Yang Y., Nolo R., Zweidler-McKay P.A., Hughes D.P. Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness. Oncogene. 2010;29:2916\u20132926. doi: 10.1038/onc.2010.62.", "ArticleIdList": ["10.1038/onc.2010.62", "PMC2874642", "20208568"]}, {"Citation": "Yi X., Deng X., Zhao Y., Deng B., Deng J., Fan H., Du Y., Hao L. Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1. Exp. Cell Res. 2020;387:111804. doi: 10.1016/j.yexcr.2019.111804.", "ArticleIdList": ["10.1016/j.yexcr.2019.111804", "31877302"]}, {"Citation": "Gan Z., Han K., Lin S., Hu H., Shen Z., Min D. Knockdown of ubiquitin-specific peptidase 39 inhibited the growth of osteosarcoma cells and induced apoptosis in vitro. Biol. Res. 2017;50:15. doi: 10.1186/s40659-017-0121-z.", "ArticleIdList": ["10.1186/s40659-017-0121-z", "PMC5389082", "28403900"]}, {"Citation": "Jiang W., Cai X., Xu T., Liu K., Yang D., Fan L., Li G., Yu X. Tripartite Motif-Containing 46 Promotes Viability and Inhibits Apoptosis of Osteosarcoma Cells by Activating NF-\u03baB Signaling Through Ubiquitination of PPAR\u03b1. Oncol. Res. 2020;28:409. doi: 10.3727/096504020X15868639303417.", "ArticleIdList": ["10.3727/096504020X15868639303417", "PMC7851538", "32295675"]}, {"Citation": "Liang J., Xing D., Li Z., Shen J., Zhao H., Li S. TRIM59 is upregulated and promotes cell proliferation and migration in human osteosarcoma. Mol. Med. Rep. 2016;13:5200\u20135206. doi: 10.3892/mmr.2016.5183.", "ArticleIdList": ["10.3892/mmr.2016.5183", "27121462"]}, {"Citation": "Zhou C., Zhang Z., Zhu X., Qian G., Zhou Y., Sun Y., Yu W., Wang J., Lu H., Lin F., et al. N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1. EBioMedicine. 2020;59:102955. doi: 10.1016/j.ebiom.2020.102955.", "ArticleIdList": ["10.1016/j.ebiom.2020.102955", "PMC7452680", "32853985"]}, {"Citation": "Zhang D., Jiang F., Wang X., Li G. Downregulation of Ubiquitin-Specific Protease 22 Inhibits Proliferation, Invasion, and Epithelial\u2013Mesenchymal Transition in Osteosarcoma Cells. Oncol. Res. 2017;25:743. doi: 10.3727/096504016X14772395226335.", "ArticleIdList": ["10.3727/096504016X14772395226335", "PMC7841257", "27983930"]}, {"Citation": "Wang Y., Leng H., Chen H., Wang L., Jiang N., Huo X., Yu B. Knockdown of UBE2T inhibits osteosarcoma cell proliferation, migration, and invasion by suppressing the PI3K/Akt signaling pathway. Oncol. Res. 2016;24:361. doi: 10.3727/096504016X14685034103310.", "ArticleIdList": ["10.3727/096504016X14685034103310", "PMC7838603", "27712593"]}, {"Citation": "Khan H., Singh A., Thapa K., Garg N., Grewal A.K., Singh T.G. Therapeutic modulation of the phosphatidylinositol 3-kinases (PI3K) pathway in cerebral ischemic injury. Brain Res. 2021;1761:147399. doi: 10.1016/j.brainres.2021.147399.", "ArticleIdList": ["10.1016/j.brainres.2021.147399", "33662337"]}, {"Citation": "Shao G., Wang R., Sun A., Wei J., Peng K., Dai Q., Yang W., Lin Q. The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells. Mol. Cancer. 2018;17:24. doi: 10.1186/s12943-018-0784-2.", "ArticleIdList": ["10.1186/s12943-018-0784-2", "PMC5817799", "29455656"]}, {"Citation": "Gamell C., Gulati T., Levav-Cohen Y., Young R.J., Do H., Pilling P., Takano E., Watkins N., Fox S.B., Russell P., et al. Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non\u2013small cell lung cancer. Sci. Signal. 2017;10:eaaf8223. doi: 10.1126/scisignal.aaf8223.", "ArticleIdList": ["10.1126/scisignal.aaf8223", "28074012"]}, {"Citation": "Liu L., Yu L., Zeng C., Long H., Duan G., Yin G., Dai X., Lin Z. E3 ubiquitin ligase HRD1 promotes lung tumorigenesis by promoting sirtuin 2 ubiquitination and degradation. Mol. Cell. Biol. 2020;40:e00257-19. doi: 10.1128/MCB.00257-19.", "ArticleIdList": ["10.1128/MCB.00257-19", "PMC7076256", "31932479"]}, {"Citation": "Pan J., Deng Q., Jiang C., Wang X., Niu T., Li H., Chen T., Jin J., Pan W., Cai X., et al. USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer. Oncogene. 2015;34:3957\u20133967. doi: 10.1038/onc.2014.327.", "ArticleIdList": ["10.1038/onc.2014.327", "25284584"]}, {"Citation": "Singh S., Singh T.G. Role of nuclear factor kappa b (Nf-\u03bab) signalling in neurodegenerative diseases: An mechanistic approach. Curr. Neuropharmacol. 2020;18:918\u2013935. doi: 10.2174/1570159X18666200207120949.", "ArticleIdList": ["10.2174/1570159X18666200207120949", "PMC7709146", "32031074"]}, {"Citation": "Ren H., Xu Y., Wang Q., Jiang J. E3 ubiquitin ligase tripartite motif-containing 71 promotes the proliferation of non-small cell lung cancer through the inhibitor of kappaB-\u03b1/nuclear factor kappaB pathway. Oncotarget. 2018;9:10880. doi: 10.18632/oncotarget.19075.", "ArticleIdList": ["10.18632/oncotarget.19075", "PMC5834285", "29541383"]}, {"Citation": "Zhang Z., Liu P., Wang J., Gong T., Zhang F., Ma J., Han N. Ubiquitin-conjugating enzyme E2C regulates apoptosis-dependent tumor progression of non-small cell lung cancer via ERK pathway. Med. Oncol. 2015;32:149. doi: 10.1007/s12032-015-0609-8.", "ArticleIdList": ["10.1007/s12032-015-0609-8", "25832867"]}, {"Citation": "Gu J., Mao W., Ren W., Xu F., Zhu Q., Lu C., Lin Z., Zhang Z., Chu Y., Liu R., et al. Ubiquitin-protein ligase E3C maintains non-small-cell lung cancer stemness by targeting AHNAK-p53 complex. Cancer Lett. 2019;443:125\u2013134. doi: 10.1016/j.canlet.2018.11.029.", "ArticleIdList": ["10.1016/j.canlet.2018.11.029", "30503554"]}, {"Citation": "Zhan W., Han T., Zhang C., Xie C., Gan M., Deng K., Fu M., Wang J.B. TRIM59 promotes the proliferation and migration of non-small cell lung cancer cells by upregulating cell cycle related proteins. PLoS ONE. 2015;10:e0142596.", "ArticleIdList": ["PMC4658198", "26599082"]}, {"Citation": "Ning J., Zhang J., Liu W., Lang Y., Xue Y., Xu S. Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. Eur. J. Histochem. 2012;56:e46. doi: 10.4081/ejh.2012.e46.", "ArticleIdList": ["10.4081/ejh.2012.e46", "PMC3567765", "23361242"]}, {"Citation": "Chan D.W., Chan C.Y., Yam J.W., Ching Y.P., Ng I.O. Prickle-1 negatively regulates Wnt/\u03b2-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. Gastroenterology. 2006;131:1218\u20131227. doi: 10.1053/j.gastro.2006.07.020.", "ArticleIdList": ["10.1053/j.gastro.2006.07.020", "17030191"]}, {"Citation": "Guo P., Ma X., Zhao W., Huai W., Li T., Qiu Y., Zhang Y., Han L. TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1\u2013TSC2 complex. Oncogene. 2018;37:478\u2013488. doi: 10.1038/onc.2017.349.", "ArticleIdList": ["10.1038/onc.2017.349", "28967907"]}, {"Citation": "Zhu L., Qin C., Li T., Ma X., Qiu Y., Lin Y., Ma D., Qin Z., Sun C., Shen X., et al. The E3 ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression by directly targeting Src protein. Cell Death Differ. 2020;27:1819\u20131831. doi: 10.1038/s41418-019-0464-9.", "ArticleIdList": ["10.1038/s41418-019-0464-9", "PMC7244582", "31802035"]}, {"Citation": "Liu J., Zhang C., Wang X.L., Ly P., Belyi V., Xu-Monette Z.Y., Young K.H., Hu W., Feng Z. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Differ. 2014;21:1792\u20131804. doi: 10.1038/cdd.2014.121.", "ArticleIdList": ["10.1038/cdd.2014.121", "PMC4211364", "25146927"]}, {"Citation": "Yang Y.F., Zhang M.F., Tian Q.H., Zhang C.Z. TRIM65 triggers \u03b2-catenin signaling via ubiquitylation of Axin1 to promote hepatocellular carcinoma. J. Cell Sci. 2017;130:3108\u20133115. doi: 10.1242/jcs.206623.", "ArticleIdList": ["10.1242/jcs.206623", "28754688"]}, {"Citation": "Tao N.N., Zhang Z.Z., Ren J.H., Zhang J., Zhou Y.J., Wong V.K., Law B.Y., Cheng S.T., Zhou H.Z., Chen W.X., et al. Overexpression of ubiquitin-conjugating enzyme E2 L3 in hepatocellular carcinoma potentiates apoptosis evasion by inhibiting the GSK3\u03b2/p65 pathway. Cancer Lett. 2020;481:1\u20134. doi: 10.1016/j.canlet.2020.03.028.", "ArticleIdList": ["10.1016/j.canlet.2020.03.028", "32268166"]}, {"Citation": "Liu L.P., Yang M., Peng Q.Z., Li M.Y., Zhang Y.S., Guo Y.H., Chen Y., Bao S.Y. UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53Biochem. Biophys. Res. Commun. 2017;493:20\u201327. doi: 10.1016/j.bbrc.2017.09.091.", "ArticleIdList": ["10.1016/j.bbrc.2017.09.091", "28935368"]}, {"Citation": "Urbanik T., K\u00f6hler B.C., Boger R.J., Woerns M.A., Heeger S., Otto G., H\u00f6velmeyer N., Galle P.R., Schuchmann M., Waisman A., et al. Down-regulation of CYLD as a trigger for NF-\u03baB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int. J. Oncol. 2011;38:121\u2013131.", "ArticleIdList": ["21109933"]}, {"Citation": "Seliger B., Fedorushchenko A., Brenner W., Ackermann A., Atkins D., Hanash S., Lichtenfels R. Ubiquitin COOH-Terminal Hydrolase 1: A Biomarker of Renal Cell Carcinoma Associated with Enhanced Tumor Cell Proliferation and Migration. Clin. Cancer Res. 2007;13:27\u201337. doi: 10.1158/1078-0432.CCR-06-0824.", "ArticleIdList": ["10.1158/1078-0432.CCR-06-0824", "17200335"]}, {"Citation": "Nanok C., Jearanaikoon P., Proungvitaya S., Limpaiboon T. Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma. Mol. Med. Rep. 2018;17:4145\u20134153. doi: 10.3892/mmr.2017.8319.", "ArticleIdList": ["10.3892/mmr.2017.8319", "29359783"]}, {"Citation": "Huang Z.J., Zhu J.J., Yang X.Y., Biskup E. NEDD4 promotes cell growth and migration via PTEN/PI3K/AKT signaling in hepatocellular carcinoma. Oncol. Lett. 2017;14:2649\u20132656. doi: 10.3892/ol.2017.6532.", "ArticleIdList": ["10.3892/ol.2017.6532", "PMC5588169", "28928809"]}, {"Citation": "Yuan R., Wang K., Hu J., Yan C., Li M., Yu X., Liu X., Lei J., Guo W., Wu L., et al. Ubiquitin-like protein FAT10 promotes the invasion and metastasis of hepatocellular carcinoma by modifying \u03b2-catenin degradation. Cancer Res. 2014;74:5287\u20135300. doi: 10.1158/0008-5472.CAN-14-0284.", "ArticleIdList": ["10.1158/0008-5472.CAN-14-0284", "25056121"]}, {"Citation": "Su D., Ma S., Shan L., Wang Y., Wang Y., Cao C., Liu B., Yang C., Wang L., Tian S., et al. Ubiquitin-specific protease 7 sustains DNA damage response and promotes cervical carcinogenesis. J. Clin. Investig. 2018;128:4280\u20134296. doi: 10.1172/JCI120518.", "ArticleIdList": ["10.1172/JCI120518", "PMC6159995", "30179224"]}, {"Citation": "Liang J., Nishi H., Bian M.L., Higuma C., Sasaki T., Ito H., Isaka K. The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth. Oncol. Rep. 2012;28:1519\u20131525. doi: 10.3892/or.2012.1949.", "ArticleIdList": ["10.3892/or.2012.1949", "22895574"]}, {"Citation": "Hu J., Meng Y., Zeng J., Zeng B., Jiang X. Ubiquitin E3 Ligase MARCH7 promotes proliferation and invasion of cervical cancer cells through VAV2-RAC1-CDC42 pathway. Oncol. Lett. 2018;16:2312\u20132318. doi: 10.3892/ol.2018.8908.", "ArticleIdList": ["10.3892/ol.2018.8908", "PMC6036418", "30008934"]}, {"Citation": "Bai M., Che Y., Lu K., Fu L. Analysis of deubiquitinase OTUD5 as a biomarker and therapeutic target for cervical cancer by bioinformatic analysis. PeerJ. 2020;8:e9146. doi: 10.7717/peerj.9146.", "ArticleIdList": ["10.7717/peerj.9146", "PMC7333649", "32655987"]}, {"Citation": "Zhang Q., Qiao L., Wang X., Ding C., Chen J.J. UHRF1 epigenetically down-regulates UbcH8 to inhibit apoptosis in cervical cancer cells. Cell Cycle. 2018;17:300\u2013308. doi: 10.1080/15384101.2017.1403686.", "ArticleIdList": ["10.1080/15384101.2017.1403686", "PMC5914733", "29157076"]}, {"Citation": "Diao W., Guo Q., Zhu C., Song Y., Feng H., Cao Y., Du M., Chen H. USP18 promotes cell proliferation and suppressed apoptosis in cervical cancer cells via activating AKT signaling pathway. BMC Cancer. 2020;20:741. doi: 10.1186/s12885-020-07241-1.", "ArticleIdList": ["10.1186/s12885-020-07241-1", "PMC7414560", "32770981"]}, {"Citation": "Aguilar-Martinez E., Morrisroe C., Sharrocks A.D. The ubiquitin ligase UBE3A dampens ERK pathway signalling in HPV E6 transformed HeLa cells. PLoS ONE. 2015;10:e0119366. doi: 10.1371/journal.pone.0119366.", "ArticleIdList": ["10.1371/journal.pone.0119366", "PMC4376912", "25815718"]}, {"Citation": "Yan M., Zhao C., Wei N., Wu X., Cui J., Xing Y. High expression of ubiquitin-specific protease 8 (USP8) is associated with poor prognosis in patients with cervical squamous cell carcinoma. Med. Sci. Mon. Int. Med. J. Exp. Clin. Res. 2018;24:4934. doi: 10.12659/MSM.909235.", "ArticleIdList": ["10.12659/MSM.909235", "PMC6067021", "30010158"]}, {"Citation": "Lin L., Zhao W., Sun B., Wang X., Liu Q. Overexpression of TRIM24 is correlated with the progression of human cervical cancer. Am. J. Transl. Res. 2017;9:620.", "ArticleIdList": ["PMC5340696", "28337289"]}, {"Citation": "Aierken G., Seyiti A., Alifu M., Kuerban G. Knockdown of tripartite-59 (TRIM59) inhibits cellular proliferation and migration in human cervical cancer cells. Oncol. Res. 2017;25:381. doi: 10.3727/096504016X14741511303522.", "ArticleIdList": ["10.3727/096504016X14741511303522", "PMC7841184", "27662486"]}, {"Citation": "Song Y., Guo Q., Gao S., Hua K. Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer. Biochem. Biophys. Res. Commun. 2018;498:686\u2013692. doi: 10.1016/j.bbrc.2018.03.046.", "ArticleIdList": ["10.1016/j.bbrc.2018.03.046", "29524410"]}, {"Citation": "Lu X., Zhuang H., Yu Q., Zhang X., Wu Z., Zhang L., Xu Y., Wu B., Yang L., Ma A., et al. Identification of the UBA2-WTIP fusion gene in acute myeloid leukemia. Exp. Cell Res. 2018;371:409\u2013416. doi: 10.1016/j.yexcr.2018.08.035.", "ArticleIdList": ["10.1016/j.yexcr.2018.08.035", "30179602"]}, {"Citation": "Seghatoleslam A., Monabbati A., Bozorg-Ghalati F., Nikseresht M., Bordbar M.R., Rahvar M., Owji A.A. Expression of UBE2Q2, a putative member of the ubiquitin-conjugating enzyme family in pediatric acute lymphoblastic leukemia. Arch. Iran. Med. 2012;15:352\u2013355.", "ArticleIdList": ["22642244"]}, {"Citation": "Luo H., Qin Y., Reu F., Ye S., Dai Y., Huang J., Wang F., Zhang D., Pan L., Zhu H., et al. Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia. J. Hematol. Oncol. 2016;9:125. doi: 10.1186/s13045-016-0356-0.", "ArticleIdList": ["10.1186/s13045-016-0356-0", "PMC5114814", "27855695"]}, {"Citation": "King B., Trimarchi T., Reavie L., Xu L., Mullenders J., Ntziachristos P., Aranda-Orgilles B., Perez-Garcia A., Shi J., Vakoc C., et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell. 2013;153:1552\u20131566. doi: 10.1016/j.cell.2013.05.041.", "ArticleIdList": ["10.1016/j.cell.2013.05.041", "PMC4146439", "23791182"]}, {"Citation": "Wang H., Bei L., Shah C.A., Huang W., Platanias L.C., Eklund E.A. The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia. Oncogene. 2018;37:2532\u20132544. doi: 10.1038/s41388-018-0131-5.", "ArticleIdList": ["10.1038/s41388-018-0131-5", "PMC5945580", "29459712"]}, {"Citation": "Wang E., Kawaoka S., Yu M., Shi J., Ni T., Yang W., Zhu J., Roeder R.G., Vakoc C.R. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia. Proc. Natl. Acad. Sci. USA. 2013;110:3901\u20133906. doi: 10.1073/pnas.1301045110.", "ArticleIdList": ["10.1073/pnas.1301045110", "PMC3593849", "23412334"]}, {"Citation": "Shan H., Li X., Xiao X., Dai Y., Huang J., Song J., Liu M., Yang L., Lei H., Tong Y., et al. USP7 deubiquitinates and stabilizes NOTCH1 in T-cell acute lymphoblastic leukemia. Signal. Transduct. Target Ther. 2018;3:29. doi: 10.1038/s41392-018-0028-3.", "ArticleIdList": ["10.1038/s41392-018-0028-3", "PMC6202415", "30370059"]}, {"Citation": "Qiu G.Z., Mao X.Y., Ma Y., Gao X.C., Wang Z., Jin M.Z., Sun W., Zou Y.X., Lin J., Fu H.L., et al. Ubiquitin-specific protease 22 acts as an oncoprotein to maintain glioma malignancy through deubiquitinating B cell-specific Moloney murine leukemia virus integration site 1 for stabilization. Cancer Sci. 2018;109:2199\u20132210. doi: 10.1111/cas.13646.", "ArticleIdList": ["10.1111/cas.13646", "PMC6029839", "29788550"]}, {"Citation": "Quint\u00e1s-Cardama A., Zhang N., Qiu Y.H., Post S., Creighton C.J., Cortes J., Coombes K.R., Kornblau S.M. Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia. Clin. Lymphoma Myeloma Leuk. 2015;15:115\u2013127. doi: 10.1016/j.clml.2014.07.011.", "ArticleIdList": ["10.1016/j.clml.2014.07.011", "PMC4560255", "25248926"]}, {"Citation": "Schneider D., Chua R.L., Molitor N., Hamdan F.H., Rettenmeier E.M., Prokakis E., Mishra V.K., Kari V., Wegwitz F., Johnsen S.A., et al. The E3 ubiquitin ligase RNF40 suppresses apoptosis in colorectal cancer cells. Clin. Epigenet. 2019;11:98. doi: 10.1186/s13148-019-0698-x.", "ArticleIdList": ["10.1186/s13148-019-0698-x", "PMC6604314", "31266541"]}, {"Citation": "Thrift A.P. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol. 2016;41:88\u201395. doi: 10.1016/j.canep.2016.01.013.", "ArticleIdList": ["10.1016/j.canep.2016.01.013", "26851752"]}, {"Citation": "Smyth E.C., Lagergren J., Fitzgerald R.C., Lordick F., Shah M.A., Lagergren P., Cunningham D. Oesophageal cancer. Nat. Rev. Dis Primers. 2017;3:17048. doi: 10.1038/nrdp.2017.48.", "ArticleIdList": ["10.1038/nrdp.2017.48", "PMC6168059", "28748917"]}, {"Citation": "Lagergren J., Smyth E., Cunningham D., Lagergren P. Oesophageal cancer. Lancet. 2017;390:2383\u20132396. doi: 10.1016/S0140-6736(17)31462-9.", "ArticleIdList": ["10.1016/S0140-6736(17)31462-9", "28648400"]}, {"Citation": "Li L., Li X., Wang W., Gao T., Shi Z. UBE2C is involved in the functions of ECRG4 on esophageal squamous cell carcinoma. Biomed. Pharmacother. 2018;98:201\u2013206. doi: 10.1016/j.biopha.2017.12.066.", "ArticleIdList": ["10.1016/j.biopha.2017.12.066", "29268240"]}, {"Citation": "Gatti V., Bernassola F., Talora C., Melino G., Peschiaroli A. The impact of the ubiquitin system in the pathogenesis of squamous cell carcinomas. Cancers. 2020;12:1595. doi: 10.3390/cancers12061595.", "ArticleIdList": ["10.3390/cancers12061595", "PMC7352818", "32560247"]}, {"Citation": "Kuwano H., Saeki H., Kawaguchi H., Sonoda K., Kitamura K., Nakashima H., Toh Y., Sugimachi K. Proliferative activity of cancer cells in front and center areas of carcinoma in situ and invasive sites of esophageal squamous-cell carcinoma. Int. J. Cancer. 1998;78:149\u2013152. doi: 10.1002/(SICI)1097-0215(19981005)78:2<149::AID-IJC4>3.0.CO;2-Z.", "ArticleIdList": ["10.1002/(SICI)1097-0215(19981005)78:2<149::AID-IJC4>3.0.CO;2-Z", "9754643"]}, {"Citation": "Park H.B., Kim J.W., Baek K.H. Regulation of Wnt signaling through ubiquitination and deubiquitination in cancers. Int. J. Mol. Sci. 2020;21:3904. doi: 10.3390/ijms21113904.", "ArticleIdList": ["10.3390/ijms21113904", "PMC7311976", "32486158"]}, {"Citation": "Moghbeli M., Abbaszadegan M.R., Golmakani E., Forghanifard M.M. Correlation of Wnt and NOTCH pathways in esophageal squamous cell carcinoma. Cell Commun. Signal. 2016;10:129\u2013135. doi: 10.1007/s12079-016-0320-3.", "ArticleIdList": ["10.1007/s12079-016-0320-3", "PMC4882302", "27041549"]}, {"Citation": "Moore D.D., Luu H.H. Osteosarcoma. Orthop. Oncol. 2014;162:65\u201392.", "ArticleIdList": ["25070231"]}, {"Citation": "Kansara M., Thomas D.M. Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 2007;26:959248. doi: 10.1089/dna.2006.0505.", "ArticleIdList": ["10.1089/dna.2006.0505", "17263592"]}, {"Citation": "Ohata Y., Ozono K. Bone and stem cells. The mechanism of osteogenic differentiation from mesenchymal stem cell. Clin. Calcium. 2014;24:501\u2013508.", "ArticleIdList": ["24681495"]}, {"Citation": "Vriend J., Reiter R.J. Melatonin, bone regulation and the ubiquitin-proteasome connection: A review. Life Sci. 2016;145:152\u2013160. doi: 10.1016/j.lfs.2015.12.031.", "ArticleIdList": ["10.1016/j.lfs.2015.12.031", "26706287"]}, {"Citation": "Franceschi R.T., Ge C., Xiao G., Roca H., Jiang D. Transcriptional regulation of osteoblasts. Cells Tissues Organs. 2009;189:144\u2013152. doi: 10.1159/000151747.", "ArticleIdList": ["10.1159/000151747", "PMC3512205", "18728356"]}, {"Citation": "Wang Z., Kang W., You Y., Pang J., Ren H., Suo Z., Liu H., Zheng Y. USP7: Novel drug target in cancer therapy. Front. Pharmacol. 2019;10:427. doi: 10.3389/fphar.2019.00427.", "ArticleIdList": ["10.3389/fphar.2019.00427", "PMC6502913", "31114498"]}, {"Citation": "Chauhan D., Tian Z., Nicholson B., Kumar K.S., Zhou B., Carrasco R., McDermott J.L., Leach C.A., Fulcinniti M., Kodrasov M.P., et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012;22:345\u2013358. doi: 10.1016/j.ccr.2012.08.007.", "ArticleIdList": ["10.1016/j.ccr.2012.08.007", "PMC3478134", "22975377"]}, {"Citation": "Ying M., Zhang L., Zhou Q., Shao X., Cao J., Zhang N., Li W., Zhu H., Yang B., He Q. The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RAR\u03b1. Oncogene. 2016;35:4358\u20134367. doi: 10.1038/onc.2015.503.", "ArticleIdList": ["10.1038/onc.2015.503", "26776160"]}, {"Citation": "De Groot P.M., Wu C.C., Carter B.W., Munden R.F. The epidemiology of lung cancer. Transl. Lung Cancer Res. 2018;7:220. doi: 10.21037/tlcr.2018.05.06.", "ArticleIdList": ["10.21037/tlcr.2018.05.06", "PMC6037963", "30050761"]}, {"Citation": "Herbst R.S., Morgensztern D., Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446\u2013454. doi: 10.1038/nature25183.", "ArticleIdList": ["10.1038/nature25183", "29364287"]}, {"Citation": "Zhao X.C., Wang G.Z., Wen Z.S., Zhou Y.C., Hu Q., Zhang B., Qu L.W., Gao S.H., Liu J., Ma L., et al. Systematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis. EBioMedicine. 2020;53:102689. doi: 10.1016/j.ebiom.2020.102689.", "ArticleIdList": ["10.1016/j.ebiom.2020.102689", "PMC7047192", "32114396"]}, {"Citation": "Jeon H.S., Jen J. TGF-2 Signaling and the Role of Inhibitory Smads in Non-small Cell Lung Cancer. J. Thorac. Oncol. 2010;5:417\u2013419. doi: 10.1097/JTO.0b013e3181ce3afd.", "ArticleIdList": ["10.1097/JTO.0b013e3181ce3afd", "PMC3637970", "20107423"]}, {"Citation": "Yu H., Li D., Zhou P., Li W. Smurf1-positive expression indicates favorable survival for resected non-small cell lung cancer patients. Int. J. Clin. Exp. Pathol. 2018;11:399.", "ArticleIdList": ["PMC6957962", "31938124"]}, {"Citation": "Xie C., Powell C., Yao M., Wu J., Dong Q. Ubiquitin-conjugating enzyme E2C: A potential cancer biomarker. Int. J. Biochem. Cell Biol. 2014;47:113\u2013117. doi: 10.1016/j.biocel.2013.11.023.", "ArticleIdList": ["10.1016/j.biocel.2013.11.023", "24361302"]}, {"Citation": "Gupta A., Khan H., Kaur A., Singh T.G. Novel Targets Explored in the Treatment of Alcohol Withdrawal Syndrome. CNS Neurol. Disord. Drug Targets. 2020;20:158\u2013173. doi: 10.2174/1871527319999201118155721.", "ArticleIdList": ["10.2174/1871527319999201118155721", "33213357"]}, {"Citation": "Cohen P.A., Jhingran A., Oaknin A., Denny L. Cervical cancer. Lancet. 2019;393:169\u2013182. doi: 10.1016/S0140-6736(18)32470-X.", "ArticleIdList": ["10.1016/S0140-6736(18)32470-X", "30638582"]}, {"Citation": "Roura E., Castellsagu\u00e9 X., Pawlita M., Travier N., Waterboer T., Margall N., Bosch F.X., De Sanjos\u00e9 S., Dillner J., Gram I.T., et al. Smoking as a major risk factor for cervical cancer and pre-cancer: Results from the EPIC cohort. Int. J. Cancer. 2014;135:453\u2013466. doi: 10.1002/ijc.28666.", "ArticleIdList": ["10.1002/ijc.28666", "24338632"]}, {"Citation": "D\u00f6hner H., Weisdorf D.J., Bloomfield C.D. Acute myeloid leukemia. N. Engl. J. Med. 2015;373:1136\u20131152. doi: 10.1056/NEJMra1406184.", "ArticleIdList": ["10.1056/NEJMra1406184", "26376137"]}, {"Citation": "Pui C.H., Relling M., Downing J.R. Acute lymphoblastic leukemia. N. Engl. J. Med. 2004;350:1535\u20131548. doi: 10.1056/NEJMra023001.", "ArticleIdList": ["10.1056/NEJMra023001", "15071128"]}, {"Citation": "Melo J.V., Hughes T.P., Apperley J.F. Chronic myeloid leukemia. ASH Educ. Program Book. 2003;1:132\u2013152. doi: 10.1182/asheducation-2003.1.132.", "ArticleIdList": ["10.1182/asheducation-2003.1.132", "14633780"]}, {"Citation": "Xu G.W., Ali M., Wood T.E., Wong D., Maclean N., Wang X., Gronda M., Skrtic M., Li X., Hurren R., et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood Am Soc Hemat. 2010;115:2251\u20132259. doi: 10.1182/blood-2009-07-231191.", "ArticleIdList": ["10.1182/blood-2009-07-231191", "PMC2920204", "20075161"]}, {"Citation": "Eliseeva E., Pati D., Diccinanni M.B., Yu A.L., Mohsin S.K., Margolin J.F., Plon S.E. Expression and localization of the CDC34 ubiquitin-conjugating enzyme in pediatric acute lymphoblastic leukemia. Cell Growth Differ. Publ. Am. J. Cancer Res. 2001;12:427\u2013434.", "ArticleIdList": ["11504708"]}, {"Citation": "Cui X., Shen W., Wang G., Huang Z., Wen D., Yang Y., Liu Y., Cui L. Ring finger protein 152 inhibits colorectal cancer cell growth and is a novel prognostic biomarker. Am. J. Transl. Res. 2018;10:3701.", "ArticleIdList": ["PMC6291686", "30662620"]}, {"Citation": "Peyser B.D., Hermone A., Salamoun J.M., Burnett J.C., Hollingshead M.G., McGrath C.F., Gussio R., Wipf P. Specific RITA modification produces hyperselective cytotoxicity while maintaining in vivo antitumor efficacy. Mol. Cancer Ther. 2019;18:1765\u20131774. doi: 10.1158/1535-7163.MCT-19-0185.", "ArticleIdList": ["10.1158/1535-7163.MCT-19-0185", "PMC6774898", "31341033"]}, {"Citation": "Coughlin K., Anchoori R., Iizuka Y., Meints J., MacNeill L., Vogel R.I., Orlowski R.Z., Lee M.K., Roden R.B., Bazzaro M. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin. Cancer Res. 2014;20:3174\u20133186. doi: 10.1158/1078-0432.CCR-13-2658.", "ArticleIdList": ["10.1158/1078-0432.CCR-13-2658", "PMC4269153", "24727327"]}, {"Citation": "Luo H., Jing B., Xia Y., Zhang Y., Hu M., Cai H., Tong Y., Zhou L., Yang L., Yang J., et al. WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia. Cancer Cell Int. 2019;19:56. doi: 10.1186/s12935-019-0773-6.", "ArticleIdList": ["10.1186/s12935-019-0773-6", "PMC6415346", "30911287"]}, {"Citation": "Soong R.S., Anchoori R.K., Roden R.B., Cho R.L., Chen Y.C., Tseng S.C., Huang Y.L., Liao P.C., Shyu Y.C. Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-\u03baB signaling. BMC Cancer. 2020;20:386. doi: 10.1186/s12885-020-06896-0.", "ArticleIdList": ["10.1186/s12885-020-06896-0", "PMC7201939", "32375699"]}, {"Citation": "Song Y., Li S., Ray A., Das D.S., Qi J., Samur M.K., Tai Y.T., Munshi N., Carrasco R.D., Chauhan D., et al. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Oncogene. 2017;36:5631\u20135638. doi: 10.1038/onc.2017.172.", "ArticleIdList": ["10.1038/onc.2017.172", "PMC5705032", "28581522"]}, {"Citation": "Wang B., Fang L., Zhao H., Xiang T., Wang D. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells. Acta Biochim. Biophys. Sin. 2012;44:685\u2013691. doi: 10.1093/abbs/gms053.", "ArticleIdList": ["10.1093/abbs/gms053", "22843172"]}, {"Citation": "Tchoghandjian A., Soub\u00e9ran A., Tabouret E., Colin C., Denicola\u00ef E., Jiguet-Jiglaire C., El-Battari A., Villard C., Baeza-Kallee N., Figarella-Branger D. Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152. Cell Death Dis. 2016;7:e2325. doi: 10.1038/cddis.2016.214.", "ArticleIdList": ["10.1038/cddis.2016.214", "PMC5108315", "27490930"]}, {"Citation": "Cai Q., Sun H., Peng Y., Lu J., Nikolovska-Coleska Z., McEachern D., Liu L., Qiu S., Yang C.Y., Miller R., et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J. Med. Chem. 2011;54:2714\u20132726. doi: 10.1021/jm101505d.", "ArticleIdList": ["10.1021/jm101505d", "PMC3520070", "21443232"]}, {"Citation": "Xia S., Zhang X., Li C., Guan H. Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling. Saudi Pharm. J. 2017;25:638\u2013643. doi: 10.1016/j.jsps.2017.04.037.", "ArticleIdList": ["10.1016/j.jsps.2017.04.037", "PMC5447451", "28579904"]}, {"Citation": "Shi C.S., Kuo K.L., Lin W.C., Chen M.S., Liu S.H., Liao S.M., Hsu C.H., Chang Y.W., Chang H.C., Huang K.H. Neddylation inhibitor, MLN4924 suppresses angiogenesis in huvecs and solid cancers: In vitro and in vivo study. Am. J. Cancer Res. 2020;10:953.", "ArticleIdList": ["PMC7136913", "32266102"]}, {"Citation": "Fu C., Zhu X., Xu P., Li Y. Pharmacological inhibition of USP7 promotes antitumor immunity and contributes to colon cancer therapy. OncoTargets Ther. 2019;12:609. doi: 10.2147/OTT.S182806.", "ArticleIdList": ["10.2147/OTT.S182806", "PMC6339463", "30697058"]}, {"Citation": "Fukui S., Nagasaka K., Miyagawa Y., Kikuchi-Koike R., Kawata Y., Kanda R., Ichinose T., Sugihara T., Hiraike H., Wada-Hiraike O., et al. The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-\u03b2/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019;10:5932. doi: 10.18632/oncotarget.27219.", "ArticleIdList": ["10.18632/oncotarget.27219", "PMC6800272", "31666925"]}, {"Citation": "Kuo K.L., Liu S.H., Lin W.C., Chow P.M., Chang Y.W., Yang S.P., Shi C.S., Hsu C.H., Liao S.M., Chang H.C., et al. The deubiquitinating enzyme inhibitor PR-619 enhances the cytotoxicity of cisplatin via the suppression of anti-apoptotic bcl-2 protein: In vitro and in vivo study. Cells. 2019;8:1268. doi: 10.3390/cells8101268.", "ArticleIdList": ["10.3390/cells8101268", "PMC6830310", "31627336"]}, {"Citation": "Sun J., Nam S., Lee C.S., Li B., Coppola D., Hamilton A.D., Dou Q.P., Sebti S.M. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res. 2001;61:1280\u20131284.", "ArticleIdList": ["11245420"]}, {"Citation": "Milacic V., Banerjee S., Landis-Piwowar K.R., Sarkar F.H., Majumdar A.P., Dou Q.P. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res. 2008;68:7283\u20137292. doi: 10.1158/0008-5472.CAN-07-6246.", "ArticleIdList": ["10.1158/0008-5472.CAN-07-6246", "PMC2556983", "18794115"]}, {"Citation": "Li L.W., Yu X.Y., Yang Y., Zhang C.P., Guo L.P., Lu S.H. Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int. J. Cancer Res. 2009;125:1505\u20131513. doi: 10.1002/ijc.24513.", "ArticleIdList": ["10.1002/ijc.24513", "19521989"]}, {"Citation": "Jung Y., Yi Y.S., Yoo D.S., Kim J.H., Yang W.S., Lee J., Park K.W., Kweon D.H., Hong S., Cho J.Y. 8-(Tosylamino) quinoline inhibits tumour progression through targeting phosphoinositide-3-kinase/Akt pathway. Pharm. Int. J. Pharm. Sci. 2013;68:146\u2013152.", "ArticleIdList": ["23469688"]}, {"Citation": "Wang X., Mazurkiewicz M., Hillert E.K., Olofsson M.H., Pierrou S., Hillertz P., Gullbo J., Selvaraju K., Paulus A., Akhtar S., et al. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Sci. Rep. 2016;6:26979. doi: 10.1038/srep26979.", "ArticleIdList": ["10.1038/srep26979", "PMC4893612", "27264969"]}, {"Citation": "Jiang L., Sun Y., Wang J., He Q., Chen X., Lan X., Chen J., Dou Q.P., Shi X., Liu J. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma. J. Exp. Clin. Cancer Res. 2019;38:453. doi: 10.1186/s13046-019-1446-y.", "ArticleIdList": ["10.1186/s13046-019-1446-y", "PMC6836452", "31694672"]}, {"Citation": "Ungermannova D., Parker S.J., Nasveschuk C.G., Wang W., Quade B., Zhang G., Kuchta R.D., Phillips A.J., Liu X. Largazole and its derivatives selectively inhibit ubiquitin activating enzyme (E1) PLoS ONE. 2012;7:e29208.", "ArticleIdList": ["PMC3261141", "22279528"]}, {"Citation": "Tsukamoto S., Hirota H., Imachi M., Fujimuro M., Onuki H., Ohta T., Yokosawa H. Himeic acid A: A new ubiquitin-activating enzyme inhibitor isolated from a marine-derived fungus, Aspergillus sp. Bioorg. Med. Chem. Lett. 2005;15:191\u2013194. doi: 10.1016/j.bmcl.2004.10.012.", "ArticleIdList": ["10.1016/j.bmcl.2004.10.012", "15582438"]}, {"Citation": "Hashimoto M., Kato H., Katsuki A., Tsukamoto S., Fujii I. Identification of the Biosynthetic Gene Cluster for Himeic Acid A: A Ubiquitin-Activating Enzyme (E1) Inhibitor in Aspergillus japonicus MF275. ChemBioChem. 2018;19:535\u2013539. doi: 10.1002/cbic.201700584.", "ArticleIdList": ["10.1002/cbic.201700584", "29314577"]}, {"Citation": "Hann Z.S., Ji C., Olsen S.K., Lu X., Lux M.C., Tan D.S., Lima C.D. Structural basis for adenylation and thioester bond formation in the ubiquitin E1. Proc. Natl. Acad. Sci. USA. 2019;116:15475\u201315484. doi: 10.1073/pnas.1905488116.", "ArticleIdList": ["10.1073/pnas.1905488116", "PMC6681703", "31235585"]}, {"Citation": "Itoh Y., Suzuki M. Design, synthesis, and biological evaluation of novel ubiquitin-activating enzyme inhibitors. Bioorg. Med. Chem. Lett. 2018;28:2723\u20132727. doi: 10.1016/j.bmcl.2018.03.004.", "ArticleIdList": ["10.1016/j.bmcl.2018.03.004", "29548576"]}, {"Citation": "Chen J., Dexheimer T.S., Ai Y., Liang Q., Villamil M.A., Inglese J., Maloney D.J., Jadhav A., Simeonov A., Zhuang Z. Selective and cell-active inhibitors of the USP1/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem. Biol. 2011;18:1390\u20131400. doi: 10.1016/j.chembiol.2011.08.014.", "ArticleIdList": ["10.1016/j.chembiol.2011.08.014", "PMC3344384", "22118673"]}, {"Citation": "Tsukamoto S., Takeuchi T., Rotinsulu H., Mangindaan R.E., van Soest R.W., Ukai K., Kobayashi H., Namikoshi M., Ohta T., Yokosawa H. Leucettamol A: A new inhibitor of Ubc13-Uev1A interaction isolated from a marine sponge, Leucetta aff. microrhaphis. Bioorg. Med. Chem. Lett. 2008;18:6319\u20136320. doi: 10.1016/j.bmcl.2008.10.110.", "ArticleIdList": ["10.1016/j.bmcl.2008.10.110", "19006668"]}, {"Citation": "Pulvino M., Liang Y., Oleksyn D., DeRan M., Van Pelt E., Shapiro J., Sanz I., Chen L., Zhao J. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood Am. Soc. Hemat. 2012;120:1668\u20131677. doi: 10.1182/blood-2012-02-406074.", "ArticleIdList": ["10.1182/blood-2012-02-406074", "PMC3429308", "22791293"]}, {"Citation": "Ushiyama S., Umaoka H., Kato H., Suwa Y., Morioka H., Rotinsulu H., Losung F., Mangindaan R.E., de Voogd N.J., Yokosawa H., et al. Manadosterols A and B, sulfonated sterol dimers inhibiting the Ubc13\u2013Uev1A interaction, isolated from the marine sponge Lissodendryx fibrosa. J. Nat. Prod. 2012;75:1495\u20131499. doi: 10.1021/np300352u.", "ArticleIdList": ["10.1021/np300352u", "22873794"]}, {"Citation": "Choi H.J., Eun J.S., Kim B.G., Kim S.Y., Jeon H., Soh Y. Vitexin, an HIF-1alpha inhibitor, has anti-metastatic potential in PC12 cells. Mol. Cells. 2006;22:291\u2013299.", "ArticleIdList": ["17202857"]}, {"Citation": "Yang Y., Ludwig R.L., Jensen J.P., Pierre S.A., Medaglia M.V., Davydov I.V., Safiran Y.J., Oberoi P., Kenten J.H., Phillips A.C., et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell. 2005;7:547\u2013559. doi: 10.1016/j.ccr.2005.04.029.", "ArticleIdList": ["10.1016/j.ccr.2005.04.029", "15950904"]}, {"Citation": "Matsuzawa M., Kakeya H., Yamaguchi J., Shoji M., Onose R., Osada H., Hayashi Y. Enantio-and Diastereoselective Total Synthesis of (+)-Panepophenanthrin, a Ubiquitin-Activating Enzyme Inhibitor, and Biological Properties of Its New Derivatives. Chem. Asian J. 2006;1:845\u2013851. doi: 10.1002/asia.200600199.", "ArticleIdList": ["10.1002/asia.200600199", "17441127"]}, {"Citation": "Vandenberghe I., Cr\u00e9ancier L., Visp\u00e9 S., Annereau J.P., Barret J.M., Pouny I., Samson A., Aussagues Y., Massiot G., Ausseil F., et al. Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis. Biochem. Pharmacol. 2008;76:453\u2013462. doi: 10.1016/j.bcp.2008.05.031.", "ArticleIdList": ["10.1016/j.bcp.2008.05.031", "18577376"]}, {"Citation": "Chen Y., Wang D.D., Wu Y.P., Su D., Zhou T.Y., Gai R.H., Fu Y.Y., Zheng L., He Q.J., Zhu H., et al. MDM2 promotes epithelial\u2013mesenchymal transition and metastasis of ovarian cancer SKOV3 cells. Br. J. Cancer. 2017;117:1192\u20131201. doi: 10.1038/bjc.2017.265.", "ArticleIdList": ["10.1038/bjc.2017.265", "PMC5674096", "28817834"]}, {"Citation": "Downey-Kopyscinski S., Daily E.W., Gautier M., Bhatt A., Florea B.I., Mitsiades C.S., Richardson P.G., Driessen C., Overkleeft H.S., Kisselev A.F. An inhibitor of proteasome \u03b22 sites sensitizes myeloma cells to immunoproteasome inhibitors. Blood Adv. 2018;2:2443\u20132451. doi: 10.1182/bloodadvances.2018016360.", "ArticleIdList": ["10.1182/bloodadvances.2018016360", "PMC6177641", "30266819"]}, {"Citation": "Niewerth D., van Meerloo J., Jansen G., Assaraf Y.G., Hendrickx T.C., Kirk C.J., Anderl J.L., Zweegman S., Kaspers G.J., Cloos J. Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924. Biochem. Pharmacol. 2014;89:43\u201351. doi: 10.1016/j.bcp.2014.02.005.", "ArticleIdList": ["10.1016/j.bcp.2014.02.005", "24552657"]}, {"Citation": "Li J., Yakushi T., Parlati F., Mackinnon A.L., Perez C., Ma Y., Carter K.P., Colayco S., Magnuson G., Brown B., et al. Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. Nat. Chem. Bio. 2017;13:486\u2013493. doi: 10.1038/nchembio.2326.", "ArticleIdList": ["10.1038/nchembio.2326", "PMC5570473", "28244987"]}, {"Citation": "Hu S., Jin Y., Liu Y., Ljungman M., Neamati N. Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines. Eur. J. Med. Chem. 2018;158:884\u2013895. doi: 10.1016/j.ejmech.2018.09.037.", "ArticleIdList": ["10.1016/j.ejmech.2018.09.037", "PMC6192546", "30253345"]}, {"Citation": "Han K.H., Kwak M., Lee T.H., Park M.S., Jeong I.H., Kim M.J., Jin J.O., Lee P.C. USP14 inhibition regulates tumorigenesis by inducing autophagy in lung cancer in vitro. Int. J. Mol. Sci. 2019;20:5300. doi: 10.3390/ijms20215300.", "ArticleIdList": ["10.3390/ijms20215300", "PMC6862215", "31653087"]}, {"Citation": "Xu L., Wang J., Yuan X., Yang S., Xu X., Li K., He Y., Wei L., Zhang J., Tian Y. IU1 suppresses proliferation of cervical cancer cells through MDM2 degradation. Int. J. Mol. Sci. 2020;16:2951. doi: 10.7150/ijbs.47999.", "ArticleIdList": ["10.7150/ijbs.47999", "PMC7545697", "33061808"]}, {"Citation": "Reinstein E., Ciechanover A. Narrative review: Protein degradation and human diseases: The ubiquitin connection. Ann. Intern. Med. 2006;145:676\u2013684. doi: 10.7326/0003-4819-145-9-200611070-00010.", "ArticleIdList": ["10.7326/0003-4819-145-9-200611070-00010", "17088581"]}, {"Citation": "Micel L.N., Tentler J.J., Smith P.G., Eckhardt G.S. Role of ubiquitin ligases and the proteasome in oncogenesis: Novel targets for anticancer therapies. J. Clin. Oncol. 2013;31:1231. doi: 10.1200/JCO.2012.44.0958.", "ArticleIdList": ["10.1200/JCO.2012.44.0958", "PMC3807137", "23358974"]}, {"Citation": "Yang Y., Kitagaki J., Dai R.M., Tsai Y.C., Lorick K.L., Ludwig R.L., Pierre S.A., Jensen J.P., Davydov I.V., Oberoi P., et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 2007;67:9472\u20139481. doi: 10.1158/0008-5472.CAN-07-0568.", "ArticleIdList": ["10.1158/0008-5472.CAN-07-0568", "17909057"]}, {"Citation": "Barghout S.H., Patel P.S., Wang X., Xu G.W., Kavanagh S., Halgas O., Zarabi S.F., Gronda M., Hurren R., Jeyaraju D.V., et al. Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia. Leukemia. 2019;33:37\u201351. doi: 10.1038/s41375-018-0167-0.", "ArticleIdList": ["10.1038/s41375-018-0167-0", "29884901"]}, {"Citation": "Zhuang J., Shirazi F., Singh R.K., Kuiatse I., Wang H., Lee H.C., Berkova Z., Berger A., Hyer M., Chattopadhyay N., et al. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. Blood Am. Soc. Hematol. 2019;133:1572\u20131584. doi: 10.1182/blood-2018-06-859686.", "ArticleIdList": ["10.1182/blood-2018-06-859686", "PMC6450433", "30737236"]}, {"Citation": "Hyer M.L., Milhollen M.A., Ciavarri J., Fleming P., Traore T., Sappal D., Huck J., Shi J., Gavin J., Brownell J., et al. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat. Med. 2018;24:186\u2013193. doi: 10.1038/nm.4474.", "ArticleIdList": ["10.1038/nm.4474", "29334375"]}, {"Citation": "Best S., Hashiguchi T., Kittai A., Bruss N., Paiva C., Okada C., Liu T., Berger A., Danilov A.V. Targeting ubiquitin-activating enzyme induces ER stress\u2013mediated apoptosis in B-cell lymphoma cells. Blood Adv. 2019;3:51\u201362. doi: 10.1182/bloodadvances.2018026880.", "ArticleIdList": ["10.1182/bloodadvances.2018026880", "PMC6325297", "30617217"]}, {"Citation": "Shen M., Schmitt S., Buac D., Dou Q.P. Targeting the ubiquitin\u2013proteasome system for cancer therapy. Expert Opin. Ther. Targets. 2013;17:1091\u20131108. doi: 10.1517/14728222.2013.815728.", "ArticleIdList": ["10.1517/14728222.2013.815728", "PMC3773690", "23822887"]}, {"Citation": "Sekizawa R., Ikeno S., Nakamura H., Naganawa H., Matsui S., Iinuma H., Takeuchi T. Panepophenanthrin, from a mushroom strain, a novel inhibitor of the ubiquitin-activating enzyme. J. Nat. Prod. 2002;65:1491\u20131493. doi: 10.1021/np020098q.", "ArticleIdList": ["10.1021/np020098q", "12398550"]}, {"Citation": "Mehta G., Ramesh S.S. Enantioselective total synthesis of (+)-panepophenanthrin, a novel inhibitor of the ubiquitin-activating enzyme. Tetrahedron Lett. 2004;45:1985\u20131987. doi: 10.1016/j.tetlet.2003.12.149.", "ArticleIdList": ["10.1016/j.tetlet.2003.12.149"]}, {"Citation": "Mori N., Yamada Y., Ikeda S., Yamasaki Y., Tsukasaki K., Tanaka Y., Tomonaga M., Yamamoto N., Fujii M. Bay 11-7082 inhibits transcription factor NF-\u03baB and induces apoptosis of HTLV-I\u2013infected T-cell lines and primary adult T-cell leukemia cells. Blood Am. Soc. Hematol. 2002;100:1828\u20131834.", "ArticleIdList": ["12176906"]}, {"Citation": "Strickson S., Campbell D.G., Emmerich C.H., Knebel A., Plater L., Ritorto M.S., Shpiro N., Cohen P. The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochem. J. 2013;451:427\u2013437. doi: 10.1042/BJ20121651.", "ArticleIdList": ["10.1042/BJ20121651", "PMC3685219", "23441730"]}, {"Citation": "Cheng J., Fan Y.H., Xu X., Zhang H., Dou J., Tang Y., Zhong X., Rojas Y., Yu Y., Zhao Y., et al. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 2014;5:e1079. doi: 10.1038/cddis.2014.54.", "ArticleIdList": ["10.1038/cddis.2014.54", "PMC3944268", "24556694"]}, {"Citation": "Garg P., Ceccarelli D.F., Keszei A.F., Kurinov I., Sicheri F., Sidhu S.S. Structural and functional analysis of ubiquitin-based inhibitors that target the backsides of E2 enzymes. J. Mol. Biol. 2020;432:952\u2013966. doi: 10.1016/j.jmb.2019.09.024.", "ArticleIdList": ["10.1016/j.jmb.2019.09.024", "PMC7054140", "31634471"]}, {"Citation": "Ceccarelli D.F., Tang X., Pelletier B., Orlicky S., Xie W., Plantevin V., Neculai D., Chou Y.C., Ogunjimi A., Al-Hakim A., et al. An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell. 2011;145:1075\u20131087. doi: 10.1016/j.cell.2011.05.039.", "ArticleIdList": ["10.1016/j.cell.2011.05.039", "21683433"]}, {"Citation": "Zhang S., Sun Y. Targeting CDC34 E2 ubiquitin conjugating enzyme for lung cancer therapy. EBioMedicine. 2020;54:102718. doi: 10.1016/j.ebiom.2020.102718.", "ArticleIdList": ["10.1016/j.ebiom.2020.102718", "PMC7136593", "32268269"]}, {"Citation": "Sanders M.A., Brahemi G., Nangia-Makker P., Balan V., Morelli M., Kothayer H., Westwell A.D., Shekhar M.P. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: Design, synthesis, identification, and functional characterization. Mol. Cancer Ther. 2013;12:373\u2013383. doi: 10.1158/1535-7163.MCT-12-0793.", "ArticleIdList": ["10.1158/1535-7163.MCT-12-0793", "PMC3840907", "23339190"]}, {"Citation": "Kothayer H., Spencer S.M., Tripathi K., Westwell A.D., Palle K. Synthesis and in vitro anticancer evaluation of some 4, 6-diamino-1, 3, 5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors. Bioorg. Med. Chem. Lett. 2016;26:2030\u20132034. doi: 10.1016/j.bmcl.2016.02.085.", "ArticleIdList": ["10.1016/j.bmcl.2016.02.085", "PMC4808444", "26965855"]}, {"Citation": "Sharma P., Nag A. CUL4A ubiquitin ligase: A promising drug target for cancer and other human diseases. Open Biol. 2014;4:130217. doi: 10.1098/rsob.130217.", "ArticleIdList": ["10.1098/rsob.130217", "PMC3938054", "24522884"]}, {"Citation": "Al-Ghabkari A., Narendran A. In vitro characterization of a potent p53-MDM2 inhibitor, RG7112 in neuroblastoma cancer cell lines. Cancer Biother. Radiopharm. 2019;34:252\u2013257. doi: 10.1089/cbr.2018.2732.", "ArticleIdList": ["10.1089/cbr.2018.2732", "30724592"]}, {"Citation": "Pan W.W., Zhou J.J., Yu C., Xu Y., Guo L.J., Zhang H.Y., Zhou D., Song F.Z., Fan H.Y. Ubiquitin E3 ligase CRL4CDT2/DCAF2 as a potential chemotherapeutic target for ovarian surface epithelial cancer. J. Biol. Chem. 2013;288:29680\u201329691. doi: 10.1074/jbc.M113.495069.", "ArticleIdList": ["10.1074/jbc.M113.495069", "PMC3795265", "23995842"]}, {"Citation": "Azmi A.S., Philip P.A., Beck F.W., Wang Z., Banerjee S., Wang S., Yang D., Sarkar F.H., Mohammad R.M. MI-219-zinc combination: A new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011;30:117\u2013126. doi: 10.1038/onc.2010.403.", "ArticleIdList": ["10.1038/onc.2010.403", "PMC3000878", "20818437"]}, {"Citation": "Zeng X., Sigoillot F., Gaur S., Choi S., Pfaff K.L., Oh D.C., Hathaway N., Dimova N., Cuny G.D., King R.W. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell. 2010;18:382\u2013395. doi: 10.1016/j.ccr.2010.08.010.", "ArticleIdList": ["10.1016/j.ccr.2010.08.010", "PMC2957475", "20951947"]}, {"Citation": "You L., Liu H., Huang J., Xie W., Wei J., Ye X., Qian W. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins. Oncotarget. 2017;8:7777. doi: 10.18632/oncotarget.13951.", "ArticleIdList": ["10.18632/oncotarget.13951", "PMC5352360", "27999193"]}, {"Citation": "Makii C., Oda K., Ikeda Y., Sone K., Hasegawa K., Uehara Y., Nishijima A., Asada K., Koso T., Fukuda T., et al. MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53. Oncotarget. 2016;7:75328. doi: 10.18632/oncotarget.12175.", "ArticleIdList": ["10.18632/oncotarget.12175", "PMC5342744", "27659536"]}, {"Citation": "Ito T., Ando H., Suzuki T., Ogura T., Hotta K., Imamura Y., Yamaguchi Y., Handa H. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345\u20131350. doi: 10.1126/science.1177319.", "ArticleIdList": ["10.1126/science.1177319", "20223979"]}, {"Citation": "Asatsuma-Okumura T., Ito T., Handa H. Molecular mechanisms of cereblon-based drugs. Pharmacol. Ther. 2019;202:132\u2013139. doi: 10.1016/j.pharmthera.2019.06.004.", "ArticleIdList": ["10.1016/j.pharmthera.2019.06.004", "31202702"]}, {"Citation": "Azmi A.S., Aboukameel A., Banerjee S., Wang Z., Mohammad M., Wu J., Wang S., Yang D., Philip P.A., Sarkar F.H., et al. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur. J. Cancer. 2010;46:1122\u20131131. doi: 10.1016/j.ejca.2010.01.015.", "ArticleIdList": ["10.1016/j.ejca.2010.01.015", "PMC4106027", "20156675"]}, {"Citation": "Kisselev A.F., Callard A., Goldberg A.L. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J. Biol. Chem. 2006;281:8582\u20138590. doi: 10.1074/jbc.M509043200.", "ArticleIdList": ["10.1074/jbc.M509043200", "16455650"]}, {"Citation": "Lawasut P., Chauhan D., Laubach J., Hayes C., Fabre C., Maglio M., Mitsiades C., Hideshima T., Anderson K.C., Richardson P.G. New proteasome inhibitors in myeloma. Curr. Hematol. Malig. Rep. 2012;7:258\u2013266. doi: 10.1007/s11899-012-0141-2.", "ArticleIdList": ["10.1007/s11899-012-0141-2", "23065395"]}, {"Citation": "McHugh A., Fernandes K., South A.P., Mellerio J.E., Salas-Alan\u00eds J.C., Proby C.M., Leigh I.M., Saville M.K. Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: The identification of mechanisms of differential sensitivity. Oncotarget. 2018;9:20265. doi: 10.18632/oncotarget.24750.", "ArticleIdList": ["10.18632/oncotarget.24750", "PMC5945540", "29755650"]}, {"Citation": "Meng L., Mohan R., Kwok B.H., Elofsson M., Sin N., Crews C.M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA. 1999;96:10403\u201310408. doi: 10.1073/pnas.96.18.10403.", "ArticleIdList": ["10.1073/pnas.96.18.10403", "PMC17900", "10468620"]}, {"Citation": "Sidor-Kaczmarek J., Cichorek M., Spodnik J.H., W\u00f3jcik S., Mory\u015b J. Proteasome inhibitors against amelanotic melanoma. Cell Biol. Toxicol. 2017;33:557\u2013573. doi: 10.1007/s10565-017-9390-0.", "ArticleIdList": ["10.1007/s10565-017-9390-0", "PMC5658467", "28281027"]}, {"Citation": "Zhou Y., Wang K., Zhen S., Wang R., Luo W. Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21Waf1/Cip1 and p27Kip1. Taiwan J. Obstet. Gynecol. 2016;55:847\u2013851. doi: 10.1016/j.tjog.2016.09.003.", "ArticleIdList": ["10.1016/j.tjog.2016.09.003", "28040131"]}, {"Citation": "Vogl D.T., Martin T.G., Vij R., Hari P., Mikhael J.R., Siegel D., Wu K.L., Delforge M., Gasparetto C. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Leuk. Lymphoma. 2017;58:1872\u20131879. doi: 10.1080/10428194.2016.1263842.", "ArticleIdList": ["10.1080/10428194.2016.1263842", "28140719"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "9", "Day": "27"}, {"Year": "2021", "Month": "10", "Day": "27"}, {"Year": "2021", "Month": "10", "Day": "28"}, {"Year": "2021", "Month": "11", "Day": "13", "Hour": "1", "Minute": "6"}, {"Year": "2021", "Month": "11", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "12", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "11", "Day": "4"}], "PublicationStatus": "epublish", "ArticleIdList": ["34769401", "PMC8584958", "10.3390/ijms222111971", "ijms222111971"]}}], "PubmedBookArticle": []}